Eli Lilly and Company

Other

Samuel James Dominianni

Alan M Warshawsky

Leonard Larry Winneroski, Jr

Lynn Stacy Gossett

Dawn Alisa Brooks

Christopher J Rito

Donald Paul Matthews

Robert J Ardecky

Russell Dean Stucky

Pierre-Yves Michellys

Margaret Mary Faul

Anthony John Shuker

John S Tyhonas

David A Hay

Guoxin Zhu

Scott Eugene Conner

Charles W Ryan

Alexander Glenn Godfrey

Allie Edward Tripp

Terence T Yen

Yanping Xu

Richard Craig Thompson

Nathan Bryan Mantlo

Klaus K Schmiegel

Richard Duane Johnston

Daniel Ray Mayhugh

Xiaodong Wang

William Harlan Gritton

Ashraf Saeed

Christopher Randall Schmid

Lora L Fitch

Garret Jay Etgen

Christopher John Rit

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is II, alkyl or haloalkyl, R4 is II, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists

The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C-Calkyl, aryl-C-alkyl, heteroaryl-C-alkyl, C-Ccycloalkylaryl-C-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C-Calkyl, C-Ccycloalkyl and heteroaryl. X is a C-Calkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH)COOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C-Calkyl, C-Calkoxy. Additionally, R4 is H, halo, a substituted or unsubstituted group selected from C-Calkyl, C-Calkoxy, C-Ccycloalkyl, arylC-Calkyl and phenyl, or R3 and R4 are combined to form a C-Ccycloalkyl.

Peroxisome proliferator activated receptor alpha agonists

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Modulators of peroxisome proliferator activated receptors

Hypoglycemic N,N-arylsulfonylglycine compounds

This invention provides compounds and their pharmaceutically acceptable salts, pharmaceutical formulation of said compounds and methods for treating hyperglycemia associated with non-insulin dependant diabetes and for treating hyperlipidemia.

Hypoglycemic sulfonyl pyrazolones and pyrazolines

This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.

Hypoglycemic and hypolipidemic compounds

This invention provides 1,2,3,4-tetrahydroisoquinoline compounds and their pharmaceuticallyacceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.

Antihyperglycemic compounds selected from the group consisting of C-substituted pentacycloazoles and N-alkyl-substituted pentacycloazoles.

Oral hypoglycemic agents

Imidazolium salts of formula I are effective in lowering blood glucose levels in mammals following administration ##STR1## wherein the various substituents are defined hereinbelow.

Imidazolium hypoglycemic agents

A process is provided which produces 3-sulfonylamino-4-aminobenzophenone intermediates useful in the regiospecific synthesis of benzimidazole antiviral agents.

3-sulfonylamino-4-aminobenzophenone derivatives

Growing community of inventors

Indianapolis, IN, United States of America

Samuel James Dominianni